Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:intradigm [2023/03/04 21:18]
liam
+++ pharmaceutical_companies:intradigm [2024/11/09 19:40] (current)
liam [External links]
@@ Line 7: / Line 7: @@
 ===== History =====
-Intradigm was founded in mid-2000 by [[:Jill Glasspool-Malone]], [[:Jim Mixson]] and [[:Martin Woodle]].((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company's non-viral gene delivery technology was originally developed by [[Genetic Therepies Inc.]] (GTI) and licensed to Intradigm by [[Novartis]] after their several attempts at [[:gene therapy]] failed.((Kirchweger, G. (2003). //Genetic Therapies Inc.: tight-lipped for now.// Molecular Therapy, 7(3), 293. https://doi.org/10.1016/s1525-0016(03)00051-0)) The license agreement was transferred to Intradigm contingent on funding from [[:Emerging Technology Partners]] and Novartis’ own venture fund.
+Intradigm was founded in mid-2000 by [[:Jill Glasspool-Malone]], [[:Jim Mixson]] and [[:Martin Woodle]].((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company's non-viral gene delivery technology was originally developed by [[Genetic Therapies, Inc.]] (GTI) and licensed to Intradigm by [[Novartis]] after their several attempts at [[:gene therapy]] failed.((Kirchweger, G. (2003). //Genetic Therapies Inc.: tight-lipped for now.// Molecular Therapy, 7(3), 293. https://doi.org/10.1016/s1525-0016(03)00051-0)) The license agreement was transferred to Intradigm contingent on funding from [[:Emerging Technology Partners]] and Novartis’ own venture fund.
+{{ :pharmaceutical_companies:2002-11-28-the-baltimore-sun-pg-c2-clip-novavax-ceo.jpg?300|}}
 Glasspool-Malone began working on the startup in August 1999 as Managing Director, helping to secure $2.3 million in venture capital funding, setting up laboratory and office facilities, and developing the company's scientific and business development plan.((//Jill Glasspool Malone.// ResearchGate. Retrieved March 4, 2023, from https://archive.ph/Z5Pgx)) Intradigm entered the [[:united_states:Maryland|State of Maryland]]'s Challenge Investment Fund program on September 20, 2000.
@@ Line 13: / Line 15: @@
 Intradigm closed its Series A round of funding in June 2001, receiving a $300,000 investment from the [[:Maryland Venture Fund]] (MVF).((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) The company "entered in to a multi-year, multi-product development program" with [[DirectGene]] in December 2001 to "jointly develop products aimed at prostate and pancreatic cancer."((//Collaborations.// DirectGene. Retrieved August 26, 2002, from https://archive.ph/GW4U5))
-On November 22, 2002, Itradigm announced it had hired former [[Novavax]] CEO [[:John Spears]] as its Chairman and CEO.((//Ex-chief of Novavax hired as Intradigm CEO.// (2002, November 28). The Baltimore Sun, C2. https://www.newspapers.com/image/248431447/?terms=Intradigm&match=1))
+On November 22, 2002, Itradigm announced it had hired former [[Novavax]] CEO [[:John Spears]] as its Chairman and CEO.((//Ex-chief of Novavax hired as Intradigm CEO.// (2002, November 28). The Baltimore Sun, C2. https://www.newspapers.com/image/248431447/?terms=Intradigm&match=1)) ((//Intradigm appoints John A. Spears Chairman and CEO.// (2002, December 2). PharmaBiz. https://archive.ph/oRzIK))
+On December 16, 2009, Intradigm was acquired by [[Silence Therapeutics]].((//Intradigm Corporation - Crunchbase Company Profile & Funding.// Crunchbase. Retrieved March 5, 2023, from https://www.crunchbase.com/organization/intradigm-corporation))
 ===== Organization =====
@@ Line 19: / Line 23: @@
 ==== Funding ====
-Investors in Intradigm include:((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf))
+Investors in Intradigm include:((Bodnar, T. (2002). //Venture Capital Funds Annual Report July 2002 (p. 27).// Maryland Department of Business & Economic Development. https://web.archive.org/web/20230304190817/https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000115/unrestricted/20030190e.pdf)) ((//Intradigm Corporation - Funding, Financials, Valuation & Investors.// Crunchbase. Retrieved March 5, 2023, from https://crunchbase.com/organization/intradigm-corporation/company_financials))
+  * [[:Alta Partners]]
+  * [[:Astellas Venture Management]]
+  * [[Eli Lilly]]
   * [[:Emerging Technology Parters]]
+  * [[:Frazier Healthcare Partners]]
   * [[:Maryland Venture Fund]]
+  * [[:MediBIC Group]]
+  * [[:MP Healthcare Venture Management]]
   * [[:Novartis Venture Fund]]
+  * [[:Roche Venture Fund]]
 ==== Personnel ====
 ^ Name  ^ Position  ^ Notes  ^
 | [[:Jill Glasspool-Malone]]  | Co-founder and Managing Director  | Wife and business partner of [[:Robert Malone]]  |
-| [[:Martin Woodle]]  | Co-founder, CEO and President  | -  |
+| [[:Martin Woodle]]  | Co-founder, CEO and President, Chief Scientific Advisor, Board Member  | -  |
 | [[:Jim Mixson]]  | Co-founder  | -  |
+| [[:John Spears]]  | CEO  | Former CEO of [[Novavax]]  |
 | [[:David Strickler]]  | VP, Operations and Finance  | -  |
 | [[:Patrick Lu]]  | Executive VP, Genomics  | -  |
@@ Line 37: / Line 48: @@
 ^  Board of Directors  ^^^
 | [[:Robert Riley]]  | Director  | -  |
+^  Scientific Advisory Board((//About Us.// Interdigm Corporation. Retrieved May 10, 2002, from https://archive.ph/pOX3Y))  ^^^
+| [[:Paul Tolstoshev]]  | Member  | Formerly Vice President of Research at [[Genetic Therapies, Inc.]]  |
+| [[:Anton Wellstein]]  | Member  | [[:Georgetown University]]  |
+| [[:Richard Heller]]  | Member  | [[:University of South Florida]]  |
+| [[:Richard Gilbert]]  | Member  | [[:University of South Florida]]  |
+| [[:Gert Storm]]  | Member  | [[:Utrecht University]]  |
+| [[:Bruce Trapnell]]  | Member  | [[:University of Cincinnati]], formerly VP for Virology of [[Genetic Therapies, Inc.]]  |
+| [[:Dexi Liu]]  | Member  | [[:University of Pittsburgh]]  |
+| [[:Joel Cohen]]  | Member  | [[:University of the Pacific]]  |
+| [[:Joel Jessee]]  | Member  | Vice President of [[Atto Bioscience]]  |
+| [[:Hamid Ghandehari]]  | Member  | [[:University of Maryland at Baltimore]]  |
+| [[:Archibald James Mixson]]  | Member  | [[:University of Maryland at Baltimore]]  |
 ===== External links =====
+  * [[https://wiki.whiteroseintelligence.com/en/Intradigm|Campfire Wiki]]
   * [[https://sites.google.com/housatonicits.com/home0004/research/intradigm-corp|Housatonic]]